NASDAQ:MRSNMersana Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mersana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.24 -0.14 (-2.60 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$5.00Now: $5.24▼$5.4050-Day Range$4.41MA: $7.08▼$9.2852-Week Range$1.32Now: $5.24▼$9.57Volume378,280 shsAverage Volume555,498 shsMarket Capitalization$238.05 millionP/E RatioN/ADividend YieldN/ABeta1.71 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Mersana Therapeutics has a potential upside of 148.1% from its current price of $5.24.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMersana Therapeutics has received 212 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMersana Therapeutics has received 185 “underperform” votes. (Add your “underperform” vote.)Community SentimentMersana Therapeutics has received 53.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote “Outperform” if you believe MRSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders39.70% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.05% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease by -6.08% in the coming year, from ($1.48) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.64 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN Previous Symbol CUSIPN/A CIK1442836 Webhttp://www.mersana.com/ Phone617-498-0020Debt Debt-to-Equity Ratio0.06 Current Ratio4.21 Quick Ratio4.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.12 million Price / Sales5.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book3.20Profitability EPS (Most Recent Fiscal Year)($0.65) Net Income$-28,210,000.00 Net Margins-66.97% Return on Equity-27.93% Return on Assets-21.78%Miscellaneous Employees86 Outstanding Shares45,430,000Market Cap$238.05 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive MRSN News and Ratings via Email Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MRSN Rates by TradingView Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions How has Mersana Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN stock has decreased by 18.9% and is now trading at $5.24. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Mersana Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mersana Therapeutics. When is Mersana Therapeutics' next earnings date? Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Mersana Therapeutics. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics Inc (NASDAQ:MRSN) issued its earnings results on Friday, February, 28th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.50 million. Mersana Therapeutics had a negative return on equity of 27.93% and a negative net margin of 66.97%. View Mersana Therapeutics' earnings history. What price target have analysts set for MRSN? 2 analysts have issued 1 year price targets for Mersana Therapeutics' stock. Their forecasts range from $13.00 to $13.00. On average, they expect Mersana Therapeutics' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 148.1% from the stock's current price. View analysts' price targets for Mersana Therapeutics. Has Mersana Therapeutics been receiving favorable news coverage? Press coverage about MRSN stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mersana Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMersana Therapeutics. Are investors shorting Mersana Therapeutics? Mersana Therapeutics saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 2,438,200 shares, a drop of 5.1% from the February 27th total of 2,570,000 shares. Based on an average daily trading volume, of 402,000 shares, the short-interest ratio is presently 6.1 days. Approximately 7.8% of the shares of the company are short sold. View Mersana Therapeutics' Current Options Chain. Who are some of Mersana Therapeutics' key competitors? Some companies that are related to Mersana Therapeutics include Madrigal Pharmaceuticals (MDGL), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Akebia Therapeutics (AKBA), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Phoenix Tree (IMAB), Phathom Pharmaceuticals (PHAT), Odonate Therapeutics (ODT), Intra-Cellular Therapies (ITCI), Rocket Pharmaceuticals (RCKT), Revance Therapeutics (RVNC), CannTrust (CNTTF), Opko Health (OPK) and Homology Medicines (FIXX). What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Amarin (AMRN), Nabriva Therapeutics (NBRV), vTv Therapeutics (VTVT), Protalix Biotherapeutics (PLX), Clearside Biomedical (CLSD), Eyepoint Pharmaceuticals (EYPT) and Fortress Biotech (FBIO). Who are Mersana Therapeutics' key executives? Mersana Therapeutics' management team includes the following people: Ms. Anna Protopapas, Pres, CEO & Director (Age 55)Mr. David A. Spellman, Chief Financial Officer (Age 42)Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)Mr. Mikhail Papisov Ph.D., Co-FounderMs. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." How do I buy shares of Mersana Therapeutics? Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $5.24. How big of a company is Mersana Therapeutics? Mersana Therapeutics has a market capitalization of $238.05 million and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe. View additional information about Mersana Therapeutics. What is Mersana Therapeutics' official website? The official website for Mersana Therapeutics is http://www.mersana.com/. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Coverage Ratio
